Analysis of serum genome-wide microRNAs for breast cancer detection
Analysis of serum genome-wide microRNAs for breast cancer detection
复制标题
用于乳腺癌检测的血清全基因组 microRNA 分析
DOI：
10.1016/j.cca.2012.02.016
复制
发表时间：
2012-07-11
影响因子：
5
通讯作者：
Ge, Qinyu
中科院分区：
文献类型：
--
作者：
Wu, Qian;Wang, Chao;Ge, Qinyu
目的：在众多的miRNAs水平分析方法中，新一代测序技术（NGS）是一种有效的全基因组水平分析方法，它不仅可以准确定量已知的miRNAs表达，还可以发现新的miRNAs。本文通过SOLiD测序技术研究乳腺癌患者血清和组织中是否有特异性miRNA作为新的生物标志物共表达。方法：采用NGS -SOLiD测序技术获得乳腺癌患者和对照组血清和组织中不同的miRNA表达谱。采用实时荧光定量PCR技术筛选和验证候选miRNA生物标志物。结果：在使用SOLiD测序的全基因组miRNA分析中，发现7种miRNA共上调（即，miR-103、miR-23 a、miR-29 a、miR-222、miR-23 b、miR-24和miR-25）。经进一步验证，乳腺癌患者血清中miR-222显著升高（P
Objective: Among methods for profiling levels of miRNAs, next-generation sequencing (NGS) has an effective one for genome-wide profiles, which not only can accurately quantify known miRNAs expression, but also discovery novel miRNAs. In this paper, we investigated that whether specific miRNAs were co-expressed in the serum and tissue of breast cancer (BC) patients as novel biomarkers by SOLiD sequencing.Methods: Different miRNA expression profiles of serum and tissue in breast cancer patients and control subjects were obtained by NGS -SOLiD sequencing. Real-time PCR was used to selected and validated candidate miRNA-biomarkers. Novel miRNAs were predicted by computational pipeline, and validated by Northern blot analysis.Results: Of genome-wide miRNA analysis using SOLiD sequencing, 7 miRNAs were found to be co-upregulated (i.e., miR-103, miR-23a, miR-29a, miR-222, miR-23b, miR-24 and miR-25). miR-222 was significantly increased in the serum of BC patients by further validation(P